# A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

> **NCT03768960** · PHASE4 · COMPLETED · sponsor: **Johnson & Johnson Private Limited** · enrollment: 150 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT03768960
- **Lead sponsor:** Johnson & Johnson Private Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-10
- **Primary completion:** 2022-07-16
- **Final completion:** 2022-07-16
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03768960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03768960, "A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03768960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*